The therapeutic benefit of transfusion presumes a direct correlation between blood oxygen carrying capacity and oxygen delivery. However, studies have shown that stored blood loses its ability to oxygenate tissues. The sequelae that can occur after transfusion (renal injury, myocardial infarction, death) are consistent with the idea that banked blood may exacerbate rather than correct anemia-induced hypoxia. We have discovered that banked blood has markedly diminished levels of nitric oxide/S-nitrosothiol (NO/SNO) bioactivity including reduced amounts of the S-nitrosylated form of hemoglobin (SNO-Hb), a major mediator of blood flow and peripheral oxygen delivery. This decline in SNO provides a mechanistic basis for the impaired vasodilatory activity of stored red blood cells (RBCs) and an explanation for why transfusion of even small amounts of blood may impair tissue perfusion. We have built on this novel finding by demonstrating that restoration of SNO-Hb levels (renitrosylation) corrects storage-induced deficiencies in RBC oxygen delivery and transfusion-induced organ dysfunction in multiple preclinical transfusion paradigms, and we have initiated clinical studies to assess the effects of transfusion on human tissue oxygenation. We have also developed first-in-class renitrosylating agents that are already undergoing clinical testing. We are positioned to provide critically needed data on the effects of transfusion on tissue oxygenation in humans and to advance the benefits of renitrosylation therapy on oxygen delivery through the following aims: 1. To advance understanding of the molecular mechanisms by which RBCs deploy SNO-based signals to regulate tissue oxygenation in fresh and stored blood. 2. To develop a device for ex vivo renitrosylation. 3. To determine if the physiologic responses to transfusion with renitrosylated RBCs are superior to untreated banked blood in a preclinical trauma model. 4. To conduct an autologous standard flow (i.e. non-trauma) transfusion study in humans with and without renitrosylation to delineate the physiologic effects of transfusion and the benefits of increased/restored SNO-Hb levels on tissue oxygenation. Collectively, our studies will provide much-needed insight into the effects of transfusion on tissue oxygenation, shed light on the mechanistic basis of adverse ischemic events associated with transfusion, and accelerate development of therapeutic approaches (repletion of SNO-Hb). Restoration of the oxygen delivery capabilities of banked blood should result in blood transfusion achieving its clinical purpose: vasodilation in the microcirculation to improve end-organ oxygen delivery in the anemic patient. To the extent that the world's supplies of banked RBCs are deficient in SNO-Hb, renitrosylation may hold significant therapeutic promise.

Public Health Relevance

/ PUBLIC HEALTH RELEVANCE Red blood cells are designed to deliver oxygen and are essential for life. Remarkably, stored blood has not been shown to improve tissue oxygenation and may actually worsen tissue perfusion. Close to 85 million units of red blood cells are administered worldwide each year so transfusion-related adverse events (including heart attack, organ injury, and death) are a major public health concern. An effective therapy to improve transfusion efficacy could have major impact on the well-being of millions of patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL126900-04
Application #
9736558
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Warren, Ronald Q
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Rizza, Salvatore; Cardaci, Simone; Montagna, Costanza et al. (2018) S-nitrosylation drives cell senescence and aging in mammals by controlling mitochondrial dynamics and mitophagy. Proc Natl Acad Sci U S A 115:E3388-E3397
Reynolds, James D; Jenkins, Trevor; Matto, Faisal et al. (2018) Pharmacologic Targeting of Red Blood Cells to Improve Tissue Oxygenation. Clin Pharmacol Ther 104:553-563
Zhou, Hua-Lin; Stomberski, Colin T; Stamler, Jonathan S (2018) Cross Talk Between S-Nitrosylation and Phosphorylation Involving Kinases and Nitrosylases. Circ Res 122:1485-1487
Matto, Faisal; Kouretas, Peter C; Smith, Richard et al. (2018) S-Nitrosohemoglobin Levels and Patient Outcome After Transfusion During Pediatric Bypass Surgery. Clin Transl Sci 11:237-243
Stamler, Jonathan S; Reynolds, James D; Hess, Douglas T (2017) Letter by Stamler et al Regarding Article, ""Nitrite and S-Nitrosohemoglobin Exchange Across the Human Cerebral and Femoral Circulation: Relationship to Basal and Exercise Blood Flow Responses to Hypoxia"". Circulation 135:e1135-e1136
Zhang, Rongli; Hess, Douglas T; Reynolds, James D et al. (2016) Hemoglobin S-nitrosylation plays an essential role in cardioprotection. J Clin Invest 126:4654-4658